Glycation is a complex process that occurs in living organisms where sugar molecules attach irreversibly to protein or lipid molecules. Increased level of glycation end products (AGEs) is associated with range of chronic diseases like diabetes, cardiovascular diseases, cancer, and neurological disorders among others. Advanced glycation end products (AGEs) are stable compounds formed during the glycation process. Increased formation and accumulation of AGEs in body tissues and blood is associated with aging process and various diseases. Glycation inhibitors and AGE-breaking agents are used to lower the levels of AGEs in the body.

The global advanced glycation end products market is estimated to be valued at US$ 3,469.95 Mn in 2024 and is expected to exhibit a CAGR of 12% over the forecast period 2023 to 2030.

Key Takeaways

Key players operating in the advanced glycation end products market are Bristol-Myers Squibb Company, Covagen, Geron Corporation, GlobeImmune Inc., Miromatrix Medical Inc., Neurimmune Holding AG, Sanofi, and others.

The market is expected to witness growth owing to rising prevalence of diabetes, increasing geriatric population, and growing research and development activities. North America dominated the global AGEs market in 2019, due to growing prevalence of diabetes and obesity. Increasing healthcare spending and presence of key players in the region drive the market. Asia Pacific market is expected to grow at fastest rate during forecast period.

Key opportunities in the market include partnerships and collaborations between research institutes and pharmaceutical companies for development of novel therapies. Companies are expanding geographically to improve accessibility and affordability of anti-AGE products globally. For instance, Neurimmune announced partnership with Biogen to develop and commercialize anti-amyloid beta protofibril antibody for treatment of Alzheimer’s disease. Miromatrix expanded its cartilage repair product portfolio with development of a novel decellularized cartilage graft in partnership with Apollo Endosurgery, Inc.

Market drivers include rising diabetic population worldwide, increasing geriatric population susceptible to age-related disease, and technological advancements in drug discovery. Diabetes is a major driver as chronic hyperglycemia leads to excessive and accelerated formation of AGEs. According to International Diabetes Federation, approximately 537 million adults (20-79 years) lived with diabetes in 2021 and the figure is anticipated to rise to 643 million by 2030. Further, aging population is vulnerable to chronic diseases with accumulation of AGEs over time contributing to development of neurological, cardiovascular, and renal complications.

Market restraints are high cost of targeted therapies and limitations of current treatments. Anti-glycation agents are generally expensive biological medications with narrow therapeutic windows. Additionally, current anti-AGE therapies are limited in their effectiveness at reducing the progression of AGE-induced tissue damage in complex diseases. Their long-term efficacy and safety profiles need further evaluation in large clinical trials. Complex associations between AGEs and disease pathogenesis pose challenges in translational research.

Segment Analysis
The anti-AGE segment dominates the advanced glycation end products market due to the growing prevalence of lifestyle diseases globally. Anti-AGE products help prevent and reduce accumulation of AGEs in the body that occurs due to excess sugar consumption, obesity, and smoking. Food supplements hold a significant share as these easy-to-consume supplements help control blood sugar levels and inhibit AGE formation.

Global Analysis
North America leads the advanced glycation end products market propelled by rising public health awareness regarding lifestyle diseases. Favorable reimbursement policies for disease management supplements boost adoption of anti-AGE supplements in the region. The Asia Pacific region is projected to witness the fastest growth during the forecast period. Rising geriatric population, growing obesity owing to sedentary lifestyles, and increasing diabetic population render sizable opportunities. Initiatives by governments to curb lifestyle diseases also support market expansion. However, high formulation and stabilization costs of anti-AGE products act as a growth barrier in emerging economies.

Priya Pandey is a dynamic and passionate editor with over three years of expertise in content editing and proofreading. Holding a bachelor's degree in biotechnology, Priya has a knack for making the content engaging. Her diverse portfolio includes editing documents across different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. Priya's meticulous attention to detail and commitment to excellence make her an invaluable asset in the world of content creation and refinement.

(LinkedIn- https://www.linkedin.com/in/priya-pandey-8417a8173/